Literature DB >> 21593568

Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics.

Rüdiger Zimmermann1, Natalia Lelental, Oliver Ganslandt, Juan Manuel Maler, Johannes Kornhuber, Piotr Lewczuk.   

Abstract

Preanalytical sample handling and storage procedures play an extremely important role in reliably measuring neurochemical dementia diagnostics (NDD) biomarkers: Aβ(1-40), Aβ(1-42), Tau, and pTau181. To test different handling and storage conditions, the following protocols were applied: (a) storage at room temperature for one week, (b) deep-freezing and thawing up to three cycles, (c) deep-freezing, thawing and keeping under +4°C for two days before the analysis, and (d) long-term stability of a deeply frozen sample. Between the first and the seventh day of the storage at room temperature, the percentage of the concentrations (compared to the starting concentrations) fluctuated: 104.3-105.3, 97.6-93.2, 100.6-96.8, and 97.9-90.2 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. Re-freezing cycles resulted in the percentage fluctuations of the concentrations: 101.1-105.5, 95.4-99.7, 98.3-100.0, and 100.5-101.4 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. Keeping previously frozen/thawed samples under +4°C for two days resulted in the percentage differences of the concentrations: +15.9, +2.2, -1.1, and -0.1 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. During long-term stability, the coefficients of linear correlation (R(2)) were: Aβ(1-40), 0.007; Aβ(1-42), 0.02; Tau, 0.011; and pTau181, 0.02, and the corresponding inter-assay coefficients of variation: 13.9%, 13.9%, 11.0%, and 10.7% for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. We conclude that the NDD biomarkers are relatively stable when the cerebrospinal fluid sample is kept at room temperature for about four days; one or two thawing/refreezing cycles do not profoundly affect the biomarkers concentrations, however three cycles result in increased unsystematic variation. The four biomarkers seem to be stable in a sample stored deeply frozen for more than two years.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593568     DOI: 10.3233/JAD-2011-110212

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

1.  Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction.

Authors:  Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-07       Impact factor: 3.575

2.  CSF biomarker variability in the Alzheimer's Association quality control program.

Authors:  Niklas Mattsson; Ulf Andreasson; Staffan Persson; Maria C Carrillo; Steven Collins; Sonia Chalbot; Neal Cutler; Diane Dufour-Rainfray; Anne M Fagan; Niels H H Heegaard; Ging-Yuek Robin Hsiung; Bradley Hyman; Khalid Iqbal; Stephan A Kaeser; Stephan A Käser; D Richard Lachno; Alberto Lleó; Piotr Lewczuk; José L Molinuevo; Piero Parchi; Axel Regeniter; Robert A Rissman; Robert Rissman; Hanna Rosenmann; Giuseppe Sancesario; Johannes Schröder; Leslie M Shaw; Charlotte E Teunissen; John Q Trojanowski; Hugo Vanderstichele; Manu Vandijck; Marcel M Verbeek; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2013-05       Impact factor: 21.566

3.  Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.

Authors:  Catherine Pan; Ané Korff; Douglas Galasko; Carmen Ginghina; Elaine Peskind; Ge Li; Joseph Quinn; Thomas J Montine; Kevin Cain; Min Shi; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.

Authors:  Adelina Orellana; Pablo García-González; Sergi Valero; Laura Montrreal; Itziar de Rojas; Isabel Hernández; Maitee Rosende-Roca; Liliana Vargas; Juan Pablo Tartari; Ester Esteban-De Antonio; Urszula Bojaryn; Leire Narvaiza; Emilio Alarcón-Martín; Montserrat Alegret; Daniel Alcolea; Alberto Lleó; Lluís Tárraga; Vanesa Pytel; Amanda Cano; Marta Marquié; Mercè Boada; Agustín Ruiz
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

Review 5.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

6.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Authors:  Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 7.  A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Sun Ah Park; Ju Hee Kang; Eun Suk Kang; Chang Seok Ki; Jee Hoon Roh; Young Chul Youn; Seong Yoon Kim; Sang Yun Kim
Journal:  J Clin Neurol       Date:  2015-04       Impact factor: 3.077

8.  Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers.

Authors:  Maria João Leitão; Inês Baldeiras; Sanna-Kaisa Herukka; Maria Pikkarainen; Ville Leinonen; Anja Hviid Simonsen; Armand Perret-Liaudet; Anthony Fourier; Isabelle Quadrio; Pedro Mota Veiga; Catarina Resende de Oliveira
Journal:  Front Neurol       Date:  2015-07-08       Impact factor: 4.003

9.  Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.

Authors:  Hugo Marcel Johan Vanderstichele; Shorena Janelidze; Leentje Demeyer; Els Coart; Erik Stoops; Victor Herbst; Kimberley Mauroo; Britta Brix; Oskar Hansson
Journal:  J Alzheimers Dis       Date:  2016-05-31       Impact factor: 4.472

10.  Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.

Authors:  Inês Baldeiras; Isabel Santana; Maria João Leitão; Helena Gens; Rui Pascoal; Miguel Tábuas-Pereira; José Beato-Coelho; Diana Duro; Maria Rosário Almeida; Catarina Resende Oliveira
Journal:  Alzheimers Res Ther       Date:  2018-03-20       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.